# PREcision Medicine through IntErrogation of Rna in the kidnEy (PREMIERE)

> **NIH NIH UH3** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2021 · $560,919

## Abstract

ABSTRACT
The kidney has developed a complex, three-dimensional architecture to serve its key functions, including
excretion of waste substances, maintenance of the internal balance for fluid and salt, blood pressure
control, and hormonal function. Understanding the roles of the individual renal cell types in these processes
in health and disease is critical to develop novel targeted therapies. Extensive studies lead by this
investigative group and others have started to identify molecular disease mechanism in renal biopsy tissues
and helped to develop novel disease markers and therapies. However, up to now these studies were
limited using biopsy tissue homogenates, making it difficult to discern the specific pathways activated in cell
types.
The PREcision Medicine through IntErrogation of Rna in the kidnEy (PREMIERE) Network will bring
investigators from three leading biomedical research institutions with diverse, complementary expertise
together. Our team has an established track record in working jointly to develop state of the art approaches
in molecular analysis of renal disease. We will set out to mine our existing compendium of thousands of
gene expression profiles from renal biopsy tissues to extract single cell signatures using advanced data
mining tools. In parallel we will develop technologies in our laboratories towards single cell analysis of renal
tissues and scale them down so that they can work on single cells extracted from small renal biopsies.
These single cell profiles will be linked to the disease states of the patients. Key signatures associated with
specific cells and diseases will be extracted and localized in the three dimensional context of the kidney
using specific RNA staining techniques in the first phase of the project. In the second phase, the analytical
strategies will be scaled up so that single cell profiles from specific groups of patients can be obtained in a
robust and reproducible manner.
To this end the PREMIERE investigators will work closely with the tissue procurement sites and the Central
Hub of the KPMP, using their 20 years of experience in team science, so that at the end of the first KPMP
funding cycle novel, cell type specific treatment targets are identified fueling the therapeutic pipelines of the
future.

## Key facts

- **NIH application ID:** 10242728
- **Project number:** 5UH3DK114907-05
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Nir Hacohen
- **Activity code:** UH3 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $560,919
- **Award type:** 5
- **Project period:** 2017-09-15 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10242728

## Citation

> US National Institutes of Health, RePORTER application 10242728, PREcision Medicine through IntErrogation of Rna in the kidnEy (PREMIERE) (5UH3DK114907-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10242728. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*